A
Affectis Pharmaceuticals
Developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases
About Affectis Pharmaceuticals
Affectis is a biopharmaceutical company focused on the development of novel drugs aimed at treating psychiatric and inflammatory disorders. The company operates in the pharmaceutical and healthcare market, targeting conditions that have significant unmet medical needs. Affectis serves a diverse range of clients, including healthcare providers, hospitals, and research institutions. The business model revolves around the research, development, and commercialization of pharmaceutical products. Revenue is generated through the sale of these drugs, as well as potential licensing agreements and partnerships with other pharmaceutical companies. The company leverages its expertise in biopharmaceuticals to bring innovative treatments to market, addressing critical health issues and improving patient outcomes.
Source: Dealroom company dataAt a glance
- Founded
- 2002
- Headquarters
- Dortmund, Germany
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
EMBL Ventures
Series A1 investor entered at this stage
EQT Life Sciences
Series B and later1 investor entered at this stage
Aescap
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Affectis Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Affectis Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.